Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Alaunos rose 21.8% after adopting amended bylaws; Cheetah Net led gainers, while Xenon dropped 27.6% after pausing study enrollment.
Stocks · News reference
Canaccord Genuity Initiates Coverage On 908 Devices with Buy Rating, Announces Price Target of $13.5
Canaccord Genuity analyst Austin Moeller initiates coverage on 908 Devices (NASDAQ:MASS) with a Buy rating and announces Price Target of $13.5.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Stifel Maintains Buy on 908 Devices, Raises Price Target to $12
Stifel analyst Daniel Arias maintains 908 Devices (NASDAQ:MASS) with a Buy and raises the price target from $10 to $12.
Roth Capital Maintains Buy on 908 Devices, Raises Price Target to $13
Roth Capital analyst Max Masucci maintains 908 Devices (NASDAQ:MASS) with a Buy and raises the price target from $11 to $13.